Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroEyes International Eye ClinicHKSE:01846 -1.82%81 Return-on-Tangible-Equity is 3.60% as of Dec. 2025, which is 70% below its 10-year median of 11.94. GuruFocus rates HKSE:01846 with a GF Score™ of 81/100 and a GF Value™ of HK$5.59 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 578 Healthcare Providers & Services companies, EuroEyes International Eye Clinic ranks worse than 61.42% on this metric.
The historical rank and industry rank for EuroEyes International Eye Clinic's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:01846'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -0.68 Med: 11.94 Max: 64.57
Current: 6.3
During the past 10 years, EuroEyes International Eye Clinic's highest Return-on-Tangible-Equity was 64.57%. The lowest was -0.68%. And the median was 11.94%.
HKSE:01846's Return-on-Tangible-Equity is ranked worse than 61.42% of 578
companies
in the Healthcare Providers & Services industry
Industry Median: 10.7
vs HKSE:01846: 6.30
EuroEyes International Eye Clinic (HKSE:01846) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
EuroEyes International Eye Clinic Return-on-Tangible-Equity Related Terms
EuroEyes International Eye Clinic Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EuroEyes International Eye Clinic Return-on-Tangible-Equity Chart
HKSE:01846 vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, EuroEyes International Eye Clinic's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EuroEyes International Eye Clinic Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, EuroEyes International Eye Clinic's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where EuroEyes International Eye Clinic's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.60% mean?
EuroEyes International Eye Clinic (HKSE:01846) has a Return-on-Tangible-Equity of 3.60% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on EuroEyes International Eye Clinic and its competitors. This is 70% below median its historical median of 11.94. According to the industry distribution chart, EuroEyes International Eye Clinic ranks #355 out of 578 companies in the Healthcare Providers & Services industry, placing it in the top 61.4%.
Is EuroEyes International Eye Clinic's Return-on-Tangible-Equity too high?
EuroEyes International Eye Clinic's current Return-on-Tangible-Equity of 3.60% is 70% below median its 10-year median of 11.94. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.70. EuroEyes International Eye Clinic's value of 3.60% is 66.4% below this industry median. Based on the distribution chart, EuroEyes International Eye Clinic ranks #355 out of 578 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, EuroEyes International Eye Clinic has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EuroEyes International Eye Clinic's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, EuroEyes International Eye Clinic ranks #355 out of 578 companies for Return-on-Tangible-Equity. This places EuroEyes International Eye Clinic in the lower half of its industry. The industry median Return-on-Tangible-Equity is 10.70. EuroEyes International Eye Clinic's value of 3.60% is 66.4% below this benchmark. While the company's 10-year median is 11.94 vs. the industry median of 10.70, EuroEyes International Eye Clinic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.70, based on 578 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. EuroEyes International Eye Clinic's current Return-on-Tangible-Equity of 3.60% is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on EuroEyes International Eye Clinic and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EuroEyes International Eye Clinic's current Return-on-Tangible-Equity is 3.60%, which is 70% below median its own 10-year median of 11.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EuroEyes International Eye Clinic stock overvalued right now?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic (HKSE:01846) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$5.59, compared to a current price of HK$2.70 — trading 51.7% below its estimated fair value. The current Return-on-Tangible-Equity is 3.60%, which is 70% below median its 10-year median of 11.94 and 66.4% below the Healthcare Providers & Services industry median of 10.70. EuroEyes International Eye Clinic's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For EuroEyes International Eye Clinic (HKSE:01846), the current Return-on-Tangible-Equity is 3.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EuroEyes International Eye Clinic (HKSE:01846) Overvalued in 2026?
Based on GuruFocus' analysis, EuroEyes International Eye Clinic stock appears to be undervalued.
The current stock price of HK$2.70 is trading 51.7% below its estimated GF Value™ of HK$5.59.
GuruFocus considers EuroEyes International Eye Clinic to be Significantly Undervalued.
Key valuation signals for HKSE:01846:
Return-on-Tangible-Equity: 3.60% (70% below median its 10-year median of 11.94)
GF Value™: HK$5.59 vs. price of HK$2.70 (51.7% below fair value)
Industry Position: 66.4% below the Healthcare Providers & Services median (#355 of 578)
No single metric tells the full story. See the HKSE:01846 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EuroEyes International Eye Clinic Ltd is principally engaged in the provision of vision correction services in Germany, Denmark, the UK, the PRC including Hong Kong, and Switzerland. The Group is a high-end vision correction service provider in Germany, PRC, the UK, Denmark, and Switzerland. Its vision correction services include refractive laser surgery, phakic lens surgery (ICL), lens exchange surgery, and others including PRK/LASEK and ICRS implantation. Its revenue categories include provision of vision correction services generate maximum revenue, training services, sales of pharmaceutical products and others. The Group's five reportable segments are Germany generate maximum revenue, Denmark, UK, Chinese Mainland, and Switzerland.
81GF Score
Get the complete analysis for HKSE:01846
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01846 has been successfully added to your 
